National Academies Press: OpenBook
Suggested Citation:"Front Matter." Institute of Medicine and National Research Council. 2014. Stem Cell Therapies: Opportunities for Ensuring the Quality and Safety of Clinical Offerings: Summary of a Joint Workshop by the Institute of Medicine, the National Academy of Sciences, and the International Society for Stem Cell Research. Washington, DC: The National Academies Press. doi: 10.17226/18746.
×

STEM CELL

THERAPIES

Opportunities for Ensuring the Quality
and Safety of Clinical Offerings

SUMMARY OF A JOINT WORKSHOP

by the Institute of Medicine,
the National Academy of Sciences, and
the International Society for Stem Cell Research

Adam C. Berger, Sarah H. Beachy, and Steve Olson, Rapporteurs

Board on Health Sciences Policy
Institute of Medicine

Board on Life Sciences
Division on Earth and Life Studies

    INSTITUTE OF MEDICINE AND
NATIONAL RESEARCH COUNCIL
                         OF THE NATIONAL ACADEMIES

THE NATIONAL ACADEMIES PRESS

Washington, D.C.

www.nap.edu

Suggested Citation:"Front Matter." Institute of Medicine and National Research Council. 2014. Stem Cell Therapies: Opportunities for Ensuring the Quality and Safety of Clinical Offerings: Summary of a Joint Workshop by the Institute of Medicine, the National Academy of Sciences, and the International Society for Stem Cell Research. Washington, DC: The National Academies Press. doi: 10.17226/18746.
×

THE NATIONAL ACADEMIES PRESS • 500 Fifth Street, NW • Washington, DC 20001

NOTICE: The workshop that is the subject of this workshop summary was approved by the Governing Board of the National Research Council, whose members are drawn from the councils of the National Academy of Sciences, the National Academy of Engineering, and the Institute of Medicine.

This project was supported by contracts between the National Academy of Sciences and the Alliance for Regenerative Medicine (unnumbered contract); California Institute for Regenerative Medicine (unnumbered contract); The Ellison Medical Foundation (Contract No. OP-CW-0405-13); Howard Hughes Medical Institute (unnumbered contract); International Society for Stem Cell Research (unnumbered contract); and U.K. Academy of Medical Sciences (unnumbered contract). The project was also sponsored by the Presidents’ Committee Funds of the National Academy of Sciences, the National Academy of Engineering, and the Institute of Medicine. The views presented in this publication do not necessarily reflect the views of the organizations or agencies that provided support for the activity.

International Standard Book Number-13: 978-0-309-30300-2
International Standard Book Number-10: 0-309-30300-1

Additional copies of this report are available for sale from the National Academies Press, 500 Fifth Street, NW, Keck 360, Washington, DC 20001; (800) 624-6242 or (202) 334-3313; http://www.nap.edu.

For more information about the Institute of Medicine, visit the IOM home page at: www.iom.edu. For more information about the National Academy of Sciences, visit the NAS home page at: http://www.nasonline.org.

Copyright 2014 by the National Academy of Sciences. All rights reserved.

Printed in the United States of America

COVER: Fluorescence microscopy of pluripotent mouse stem cells undergoing differentiation into a variety of cell lineages. Photo credit: Pablo Perez-Pinera, Jonathan Brunger, Farshid Guilak, and Charles Gersbach, Duke University.

Suggested citation: IOM (Institute of Medicine) and NAS (National Academy of Sciences). 2014. Stem cell therapies: Opportunities for ensuring the quality and safety of clinical offerings. Washington, DC: The National Academies Press.

Suggested Citation:"Front Matter." Institute of Medicine and National Research Council. 2014. Stem Cell Therapies: Opportunities for Ensuring the Quality and Safety of Clinical Offerings: Summary of a Joint Workshop by the Institute of Medicine, the National Academy of Sciences, and the International Society for Stem Cell Research. Washington, DC: The National Academies Press. doi: 10.17226/18746.
×

THE NATIONAL ACADEMIES

Advisers to the Nation on Science, Engineering, and Medicine

The National Academy of Sciences is a private, nonprofit, self-perpetuating society of distinguished scholars engaged in scientific and engineering research, dedicated to the furtherance of science and technology and to their use for the general welfare. Upon the authority of the charter granted to it by the Congress in 1863, the Academy has a mandate that requires it to advise the federal government on scientific and technical matters. Dr. Ralph J. Cicerone is president of the National Academy of Sciences.

The National Academy of Engineering was established in 1964, under the charter of the National Academy of Sciences, as a parallel organization of outstanding engineers. It is autonomous in its administration and in the selection of its members, sharing with the National Academy of Sciences the responsibility for advising the federal government. The National Academy of Engineering also sponsors engineering programs aimed at meeting national needs, encourages education and research, and recognizes the superior achievements of engineers. Dr. C. D. Mote, Jr., is president of the National Academy of Engineering.

The Institute of Medicine was established in 1970 by the National Academy of Sciences to secure the services of eminent members of appropriate professions in the examination of policy matters pertaining to the health of the public. The Institute acts under the responsibility given to the National Academy of Sciences by its congressional charter to be an adviser to the federal government and, upon its own initiative, to identify issues of medical care, research, and education. Dr. Harvey V. Fineberg is president of the Institute of Medicine.

The National Research Council was organized by the National Academy of Sciences in 1916 to associate the broad community of science and technology with the Academy’s purposes of furthering knowledge and advising the federal government. Functioning in accordance with general policies determined by the Academy, the Council has become the principal operating agency of both the National Academy of Sciences and the National Academy of Engineering in providing services to the government, the public, and the scientific and engineering communities. The Council is administered jointly by both Academies and the Institute of Medicine. Dr. Ralph J. Cicerone and Dr. C. D. Mote, Jr., are chair and vice chair, respectively, of the National Research Council.

www.national-academies.org

Suggested Citation:"Front Matter." Institute of Medicine and National Research Council. 2014. Stem Cell Therapies: Opportunities for Ensuring the Quality and Safety of Clinical Offerings: Summary of a Joint Workshop by the Institute of Medicine, the National Academy of Sciences, and the International Society for Stem Cell Research. Washington, DC: The National Academies Press. doi: 10.17226/18746.
×

This page intentionally left blank.

Suggested Citation:"Front Matter." Institute of Medicine and National Research Council. 2014. Stem Cell Therapies: Opportunities for Ensuring the Quality and Safety of Clinical Offerings: Summary of a Joint Workshop by the Institute of Medicine, the National Academy of Sciences, and the International Society for Stem Cell Research. Washington, DC: The National Academies Press. doi: 10.17226/18746.
×

PLANNING COMMITTEE1

R. ALTA CHARO (Chair), Warren P. Knowles Professor of Law and Bioethics, School of Law and Department of Medical History and Bioethics, School of Medicine and Public Health, University of Wisconsin–Madison

ROBIN ALI, Professor of Human Molecular Genetics, Institute of Ophthalmology, University College London, UK

I. GLENN COHEN, Professor of Law and Co-Director of the Petrie–Flom Center for Health Law Policy, Biotechnology and Bioethics, Harvard Law School, Cambridge, MA

ELLEN G. FEIGAL, Senior Vice President, Research and Development, California Institute for Regenerative Medicine, San Francisco, CA

FRED H. GAGE, Vi and John Adler Professor, Laboratory of Genetics, Salk Institute for Biological Studies, La Jolla, CA

LAWRENCE S. B. GOLDSTEIN, Distinguished Professor and Director of the University of California, San Diego, Stem Cell Program, Department of Cellular and Molecular Medicine, University of California, San Diego, School of Medicine, La Jolla, CA

GEOFF MACKAY, Chief Executive Officer, Organogenesis, Inc., Canton, MA

AMY COMSTOCK RICK, Chief Executive Officer, Parkinson’s Action Network, Washington, DC

IRVING L. WEISSMAN, Director, Institute of Stem Cell Biology and Regenerative Medicine; Director, Ludwig Center at Stanford; Professor, Departments of Pathology and Developmental Biology and Neurosurgery, Stanford University School of Medicine, Stanford, CA

Institute of Medicine and National Research Council Staff

ADAM C. BERGER, Project Director

KEEGAN SAWYER, Program Officer

SARAH H. BEACHY, Associate Program Officer

Y. CRYSTI PARK, Senior Program Assistant

MEREDITH L. HACKMANN, Senior Program Assistant (from January 2014)

__________________

1Planning committees are solely responsible for organizing the workshop, identifying topics, and choosing speakers. The responsibility for the published workshop summary rests with the workshop rapporteurs and the institution.

Suggested Citation:"Front Matter." Institute of Medicine and National Research Council. 2014. Stem Cell Therapies: Opportunities for Ensuring the Quality and Safety of Clinical Offerings: Summary of a Joint Workshop by the Institute of Medicine, the National Academy of Sciences, and the International Society for Stem Cell Research. Washington, DC: The National Academies Press. doi: 10.17226/18746.
×

International Society for Stem Cell Research Staff

NANCY WITTY, Executive Director

HEATHER ROOKE, Scientific Director

Suggested Citation:"Front Matter." Institute of Medicine and National Research Council. 2014. Stem Cell Therapies: Opportunities for Ensuring the Quality and Safety of Clinical Offerings: Summary of a Joint Workshop by the Institute of Medicine, the National Academy of Sciences, and the International Society for Stem Cell Research. Washington, DC: The National Academies Press. doi: 10.17226/18746.
×

BOARD ON HEALTH SCIENCES POLICY

JEFFREY KAHN (Chair), Levi Professor of Bioethics and Public Policy, Berman Institute of Bioethics, Johns Hopkins University, Baltimore, MD

ELI ADASHI, Professor of Medical Science, The Warren Alpert Medical School, Brown University, Providence, RI

WYLIE BURKE, Professor and Chair, Department of Bioethics and Humanities, University of Washington, Seattle

ROBERT M. CALIFF, Director, Duke Translational Medicine Institute; Professor of Medicine, Vice Chancellor for Clinical and Translational Research, Duke University Medical Center, Durham, NC

KATHLEEN A. DRACUP, Professor, School of Nursing, University of California, San Francisco

MICHAEL EHLERS, Senior Vice President, Chief Scientific Officer of Neuroscience, Pfizer Inc., Cambridge, MA

NAOMI L. GERBER, University Professor, Center for the Study of Chronic Illness and Disability, George Mason University, Fairfax, VA

LEWIS R. GOLDFRANK, Herbert W. Adams Professor and Chair, Department of Emergency Medicine, New York University School of Medicine; Director of Emergency Medicine, Bellevue Hospital Center and New York University Langone Medical Center

STEVEN E. HYMAN, Director, Stanley Center, Broad Insitute of Harvard University and the Massachusetts Institute of Technology, Cambridge, MA

HARRY T. ORR, Director, Institute of Human Genetics; Tulloch Professor of Genetics, Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis

SHARON TERRY, President and Chief Executive Officer, Genetic Alliance, Washington, DC

REED V. TUCKSON, Managing Director, Tuckson Health Connections, LLC, Edina, MN

CLYDE YANCY, Magerstadt Professor of Medicine and Chief, Division of Cardiology, Northwestern University Feinberg School of Medicine; Associate Director, Bluhm Cardiovascular Insitute, Northwestern Memorial Hospital, Chicago, IL

Page viii Cite
Suggested Citation:"Front Matter." Institute of Medicine and National Research Council. 2014. Stem Cell Therapies: Opportunities for Ensuring the Quality and Safety of Clinical Offerings: Summary of a Joint Workshop by the Institute of Medicine, the National Academy of Sciences, and the International Society for Stem Cell Research. Washington, DC: The National Academies Press. doi: 10.17226/18746.
×

Board on Health Sciences Policy Staff

ANDREW M. POPE, Director

ADAM C. BERGER, Senior Program Officer

SARAH H. BEACHY, Associate Program Officer

Y. CRYSTI PARK, Senior Program Assistant

MEREDITH L. HACKMANN, Senior Program Assistant (from January 2014)

DONNA RANDALL, Administrative Assistant

Suggested Citation:"Front Matter." Institute of Medicine and National Research Council. 2014. Stem Cell Therapies: Opportunities for Ensuring the Quality and Safety of Clinical Offerings: Summary of a Joint Workshop by the Institute of Medicine, the National Academy of Sciences, and the International Society for Stem Cell Research. Washington, DC: The National Academies Press. doi: 10.17226/18746.
×

BOARD ON LIFE SCIENCES

JAMES P. COLLINS (Chair), Virginia M. Ullman Professor of Natural History and the Environment, Arizona State University, Tempe

ENRIQUETA C. BOND, Former President, Burroughs Wellcome Fund, Marshall, VA

ROGER D. CONE, Professor and Chairman, Department of Molecular Physiology and Biophysics; Director, Vanderbilt Institute for Obesity and Metabolism; Vanderbilt University Medical Center, Nashville, TN

SEAN EDDY, Group Leader, Howard Hughes Medical Institute, Janelia Farm Research Campus, Ashburn, VA

SARAH C. R. ELGIN, Viktor Hamburger Professor of Arts & Sciences, Department of Biology, Washington University, St. Louis, MO

DAVID R. FRANZ, Former Commander, U.S. Army Medical Research Institute of Infectious Diseases, Frederick, MD

LOUIS J. GROSS, James R. Cox and Alvan and Sally Beaman Distinguished Professor of Ecology and Evolutionary Biology and Mathematics; Director, National Institute for Mathematical and Biological Synthesis; Director, Institute for Environmental Modeling; University of Tennessee, Knoxville

ELIZABETH HEITMAN, Associate Professor of Medicine and Anesthesiology, Vanderbilt University Medical Center, Nashville, TN

JOHN G. HILDEBRAND, Regents Professor, University of Arizona, Tucson

RICHARD A. JOHNSON, Retired Partner, Arnold & Porter, LLC, Washington, DC

JUDITH KIMBLE, Vilas Professor, Howard Hughes Medical Institute Investigator, University of Wisconsin–Madison

CATO T. LAURENCIN, University Professor, University of Connecticut Health Center, Farmington

ALAN I. LESHNER, Chief Executive Officer, American Association for the Advancement of Science, Washington, DC

KAREN E. NELSON, President, J. Craig Venter Institute, Rockville, MD

ROBERT M. NEREM, Parker H. Petit Distinguished Chair for Engineering in Medicine; Institute Professor Emeritus, Georgia Institute of Technology, Atlanta

CAMILLE PARMESAN, Professor, University of Texas, Austin; National Marine Aquarium Chair, Plymouth University, Plymouth, UK

ALISON G. POWER, Professor, Cornell University, Ithaca, NY

Suggested Citation:"Front Matter." Institute of Medicine and National Research Council. 2014. Stem Cell Therapies: Opportunities for Ensuring the Quality and Safety of Clinical Offerings: Summary of a Joint Workshop by the Institute of Medicine, the National Academy of Sciences, and the International Society for Stem Cell Research. Washington, DC: The National Academies Press. doi: 10.17226/18746.
×

MARGARET RILEY, Professor, University of Massachusetts; President and Founder, Massachusetts Academy of Sciences, Amherst

JANIS C. WEEKS, Professor, University of Oregon, Eugene

MARY WOOLLEY, President, Research!America, Alexandria, VA

Board on Life Sciences Staff

FRANCES E. SHARPLES, Director

KEEGAN SAWYER, Program Officer

Suggested Citation:"Front Matter." Institute of Medicine and National Research Council. 2014. Stem Cell Therapies: Opportunities for Ensuring the Quality and Safety of Clinical Offerings: Summary of a Joint Workshop by the Institute of Medicine, the National Academy of Sciences, and the International Society for Stem Cell Research. Washington, DC: The National Academies Press. doi: 10.17226/18746.
×

Reviewers

This workshop summary has been reviewed in draft form by individuals chosen for their diverse perspectives and technical expertise, in accordance with procedures approved by the National Research Council’s Report Review Committee. The purpose of this independent review is to provide candid and critical comments that will assist the institution in making its published workshop summary as sound as possible and to ensure that the report meets institutional standards for objectivity, evidence, and responsiveness to the study charge. The review comments and draft manuscript remain confidential to protect the integrity of the process. We wish to thank the following individuals for their review of this workshop summary:

I. Glenn Cohen, Harvard Law School

Susan Howley, Christopher & Dana Reeve Foundation

Mahendra Rao, National Institutes of Health

Celia Witten, U.S. Food and Drug Administration

Although the reviewers listed above have provided many constructive comments and suggestions, they did not see the final draft of the workshop summary before its release. The review of this workshop summary was overseen by Caswell Evans, University of Illinois at Chicago, and Harold J. Fallon, University of Alabama at Birmingham School of Medicine. Appointed by the National Research Council and the Institute of Medicine, they were responsible for making certain that an independent examination of this workshop summary was carried out in accordance with institutional procedures and that all review comments

Suggested Citation:"Front Matter." Institute of Medicine and National Research Council. 2014. Stem Cell Therapies: Opportunities for Ensuring the Quality and Safety of Clinical Offerings: Summary of a Joint Workshop by the Institute of Medicine, the National Academy of Sciences, and the International Society for Stem Cell Research. Washington, DC: The National Academies Press. doi: 10.17226/18746.
×

were carefully considered. Responsibility for the final content of this workshop summary rests entirely with the rapporteurs and the institution.

Page xiii Cite
Suggested Citation:"Front Matter." Institute of Medicine and National Research Council. 2014. Stem Cell Therapies: Opportunities for Ensuring the Quality and Safety of Clinical Offerings: Summary of a Joint Workshop by the Institute of Medicine, the National Academy of Sciences, and the International Society for Stem Cell Research. Washington, DC: The National Academies Press. doi: 10.17226/18746.
×

Acknowledgments

The support of the sponsors of Stem Cell Therapies: Opportunities for Ensuring the Quality and Safety of Clinical Offerings was crucial to the planning and conduct of the workshop and the development of the workshop summary report. Sponsorship was provided by the Alliance for Regenerative Medicine; California Institute for Regenerative Medicine; The Ellison Medical Foundation; Howard Hughes Medical Institute; International Society for Stem Cell Research; the Presidents’ Committee Funds of the National Academy of Sciences, the National Academy of Engineering, and the Institute of Medicine; and U.K. Academy of Medical Sciences.

The planning committee and staff wish to express their gratitude to the expert speakers whose presentations helped outline the challenges and opportunities for ensuring the quality and safety of stem cell therapies. The staff also wish to thank the members of the planning committee for their work in developing an excellent workshop agenda. The project director would like to thank project staff, who worked diligently to develop both the workshop and the resulting summary.

Suggested Citation:"Front Matter." Institute of Medicine and National Research Council. 2014. Stem Cell Therapies: Opportunities for Ensuring the Quality and Safety of Clinical Offerings: Summary of a Joint Workshop by the Institute of Medicine, the National Academy of Sciences, and the International Society for Stem Cell Research. Washington, DC: The National Academies Press. doi: 10.17226/18746.
×

This page intentionally left blank.

Suggested Citation:"Front Matter." Institute of Medicine and National Research Council. 2014. Stem Cell Therapies: Opportunities for Ensuring the Quality and Safety of Clinical Offerings: Summary of a Joint Workshop by the Institute of Medicine, the National Academy of Sciences, and the International Society for Stem Cell Research. Washington, DC: The National Academies Press. doi: 10.17226/18746.
×
Page xviii Cite
Suggested Citation:"Front Matter." Institute of Medicine and National Research Council. 2014. Stem Cell Therapies: Opportunities for Ensuring the Quality and Safety of Clinical Offerings: Summary of a Joint Workshop by the Institute of Medicine, the National Academy of Sciences, and the International Society for Stem Cell Research. Washington, DC: The National Academies Press. doi: 10.17226/18746.
×
Suggested Citation:"Front Matter." Institute of Medicine and National Research Council. 2014. Stem Cell Therapies: Opportunities for Ensuring the Quality and Safety of Clinical Offerings: Summary of a Joint Workshop by the Institute of Medicine, the National Academy of Sciences, and the International Society for Stem Cell Research. Washington, DC: The National Academies Press. doi: 10.17226/18746.
×

Abbreviations and Acronyms

AIDS

acquired immunodeficiency syndrome

ASRM

American Society for Reproductive Medicine

CAS

Chinese Academy of Sciences

CEO

chief executive officer

CIRM

California Institute for Regenerative Medicine

COFEPRIS

Comisión Federal para la Protección contra Riesgos Sanitarios (Mexico)

EMA

European Medicines Agency

FDA

U.S. Food and Drug Administration

FTC

Federal Trade Commission

GMP

good manufacturing process

IOM

Institute of Medicine

IRB

institutional review board

ISCT

International Society for Cellular Therapy

ISSCR

International Society for Stem Cell Research

MHLW

Ministry of Health, Labor, and Welfare (Japan)

MS

multiple sclerosis

NAS

National Academy of Sciences

PMDA

Pharmaceuticals and Medical Devices Agency (Japan)

Suggested Citation:"Front Matter." Institute of Medicine and National Research Council. 2014. Stem Cell Therapies: Opportunities for Ensuring the Quality and Safety of Clinical Offerings: Summary of a Joint Workshop by the Institute of Medicine, the National Academy of Sciences, and the International Society for Stem Cell Research. Washington, DC: The National Academies Press. doi: 10.17226/18746.
×

SART

Society for Assisted Reproductive Technologies

U.S.

United States

Suggested Citation:"Front Matter." Institute of Medicine and National Research Council. 2014. Stem Cell Therapies: Opportunities for Ensuring the Quality and Safety of Clinical Offerings: Summary of a Joint Workshop by the Institute of Medicine, the National Academy of Sciences, and the International Society for Stem Cell Research. Washington, DC: The National Academies Press. doi: 10.17226/18746.
×
Page R1
Suggested Citation:"Front Matter." Institute of Medicine and National Research Council. 2014. Stem Cell Therapies: Opportunities for Ensuring the Quality and Safety of Clinical Offerings: Summary of a Joint Workshop by the Institute of Medicine, the National Academy of Sciences, and the International Society for Stem Cell Research. Washington, DC: The National Academies Press. doi: 10.17226/18746.
×
Page R2
Suggested Citation:"Front Matter." Institute of Medicine and National Research Council. 2014. Stem Cell Therapies: Opportunities for Ensuring the Quality and Safety of Clinical Offerings: Summary of a Joint Workshop by the Institute of Medicine, the National Academy of Sciences, and the International Society for Stem Cell Research. Washington, DC: The National Academies Press. doi: 10.17226/18746.
×
Page R3
Suggested Citation:"Front Matter." Institute of Medicine and National Research Council. 2014. Stem Cell Therapies: Opportunities for Ensuring the Quality and Safety of Clinical Offerings: Summary of a Joint Workshop by the Institute of Medicine, the National Academy of Sciences, and the International Society for Stem Cell Research. Washington, DC: The National Academies Press. doi: 10.17226/18746.
×
Page R4
Suggested Citation:"Front Matter." Institute of Medicine and National Research Council. 2014. Stem Cell Therapies: Opportunities for Ensuring the Quality and Safety of Clinical Offerings: Summary of a Joint Workshop by the Institute of Medicine, the National Academy of Sciences, and the International Society for Stem Cell Research. Washington, DC: The National Academies Press. doi: 10.17226/18746.
×
Page R5
Suggested Citation:"Front Matter." Institute of Medicine and National Research Council. 2014. Stem Cell Therapies: Opportunities for Ensuring the Quality and Safety of Clinical Offerings: Summary of a Joint Workshop by the Institute of Medicine, the National Academy of Sciences, and the International Society for Stem Cell Research. Washington, DC: The National Academies Press. doi: 10.17226/18746.
×
Page R6
Suggested Citation:"Front Matter." Institute of Medicine and National Research Council. 2014. Stem Cell Therapies: Opportunities for Ensuring the Quality and Safety of Clinical Offerings: Summary of a Joint Workshop by the Institute of Medicine, the National Academy of Sciences, and the International Society for Stem Cell Research. Washington, DC: The National Academies Press. doi: 10.17226/18746.
×
Page R7
Page viii Cite
Suggested Citation:"Front Matter." Institute of Medicine and National Research Council. 2014. Stem Cell Therapies: Opportunities for Ensuring the Quality and Safety of Clinical Offerings: Summary of a Joint Workshop by the Institute of Medicine, the National Academy of Sciences, and the International Society for Stem Cell Research. Washington, DC: The National Academies Press. doi: 10.17226/18746.
×
Page R8
Suggested Citation:"Front Matter." Institute of Medicine and National Research Council. 2014. Stem Cell Therapies: Opportunities for Ensuring the Quality and Safety of Clinical Offerings: Summary of a Joint Workshop by the Institute of Medicine, the National Academy of Sciences, and the International Society for Stem Cell Research. Washington, DC: The National Academies Press. doi: 10.17226/18746.
×
Page R9
Suggested Citation:"Front Matter." Institute of Medicine and National Research Council. 2014. Stem Cell Therapies: Opportunities for Ensuring the Quality and Safety of Clinical Offerings: Summary of a Joint Workshop by the Institute of Medicine, the National Academy of Sciences, and the International Society for Stem Cell Research. Washington, DC: The National Academies Press. doi: 10.17226/18746.
×
Page R10
Suggested Citation:"Front Matter." Institute of Medicine and National Research Council. 2014. Stem Cell Therapies: Opportunities for Ensuring the Quality and Safety of Clinical Offerings: Summary of a Joint Workshop by the Institute of Medicine, the National Academy of Sciences, and the International Society for Stem Cell Research. Washington, DC: The National Academies Press. doi: 10.17226/18746.
×
Page R11
Suggested Citation:"Front Matter." Institute of Medicine and National Research Council. 2014. Stem Cell Therapies: Opportunities for Ensuring the Quality and Safety of Clinical Offerings: Summary of a Joint Workshop by the Institute of Medicine, the National Academy of Sciences, and the International Society for Stem Cell Research. Washington, DC: The National Academies Press. doi: 10.17226/18746.
×
Page R12
Page xiii Cite
Suggested Citation:"Front Matter." Institute of Medicine and National Research Council. 2014. Stem Cell Therapies: Opportunities for Ensuring the Quality and Safety of Clinical Offerings: Summary of a Joint Workshop by the Institute of Medicine, the National Academy of Sciences, and the International Society for Stem Cell Research. Washington, DC: The National Academies Press. doi: 10.17226/18746.
×
Page R13
Suggested Citation:"Front Matter." Institute of Medicine and National Research Council. 2014. Stem Cell Therapies: Opportunities for Ensuring the Quality and Safety of Clinical Offerings: Summary of a Joint Workshop by the Institute of Medicine, the National Academy of Sciences, and the International Society for Stem Cell Research. Washington, DC: The National Academies Press. doi: 10.17226/18746.
×
Page R14
Suggested Citation:"Front Matter." Institute of Medicine and National Research Council. 2014. Stem Cell Therapies: Opportunities for Ensuring the Quality and Safety of Clinical Offerings: Summary of a Joint Workshop by the Institute of Medicine, the National Academy of Sciences, and the International Society for Stem Cell Research. Washington, DC: The National Academies Press. doi: 10.17226/18746.
×
Page R15
Suggested Citation:"Front Matter." Institute of Medicine and National Research Council. 2014. Stem Cell Therapies: Opportunities for Ensuring the Quality and Safety of Clinical Offerings: Summary of a Joint Workshop by the Institute of Medicine, the National Academy of Sciences, and the International Society for Stem Cell Research. Washington, DC: The National Academies Press. doi: 10.17226/18746.
×
Page R16
Page xvii Cite
Suggested Citation:"Front Matter." Institute of Medicine and National Research Council. 2014. Stem Cell Therapies: Opportunities for Ensuring the Quality and Safety of Clinical Offerings: Summary of a Joint Workshop by the Institute of Medicine, the National Academy of Sciences, and the International Society for Stem Cell Research. Washington, DC: The National Academies Press. doi: 10.17226/18746.
×
Page R17
Page xviii Cite
Suggested Citation:"Front Matter." Institute of Medicine and National Research Council. 2014. Stem Cell Therapies: Opportunities for Ensuring the Quality and Safety of Clinical Offerings: Summary of a Joint Workshop by the Institute of Medicine, the National Academy of Sciences, and the International Society for Stem Cell Research. Washington, DC: The National Academies Press. doi: 10.17226/18746.
×
Page R18
Suggested Citation:"Front Matter." Institute of Medicine and National Research Council. 2014. Stem Cell Therapies: Opportunities for Ensuring the Quality and Safety of Clinical Offerings: Summary of a Joint Workshop by the Institute of Medicine, the National Academy of Sciences, and the International Society for Stem Cell Research. Washington, DC: The National Academies Press. doi: 10.17226/18746.
×
Page R19
Suggested Citation:"Front Matter." Institute of Medicine and National Research Council. 2014. Stem Cell Therapies: Opportunities for Ensuring the Quality and Safety of Clinical Offerings: Summary of a Joint Workshop by the Institute of Medicine, the National Academy of Sciences, and the International Society for Stem Cell Research. Washington, DC: The National Academies Press. doi: 10.17226/18746.
×
Page R20
Next: 1 Introduction and Themes of the Workshop »
Stem Cell Therapies: Opportunities for Ensuring the Quality and Safety of Clinical Offerings: Summary of a Joint Workshop by the Institute of Medicine, the National Academy of Sciences, and the International Society for Stem Cell Research Get This Book
×
Buy Paperback | $40.00 Buy Ebook | $31.99
MyNAP members save 10% online.
Login or Register to save!
Download Free PDF

Stem cells offer tremendous promise for advancing health and medicine. Whether being used to replace damaged cells and organs or else by supporting the body's intrinsic repair mechanisms, stem cells hold the potential to treat such debilitating conditions as Parkinson's disease, diabetes, and spinal cord injury. Clinical trials of stem cell treatments are under way in countries around the world, but the evidence base to support the medical use of stem cells remains limited. Despite this paucity of clinical evidence, consumer demand for treatments using stem cells has risen, driven in part by a lack of available treatment options for debilitating diseases as well as direct-to-consumer advertising and public portrayals of stem cell-based treatments. Clinics that offer stem cell therapies for a wide range of diseases and conditions have been established throughout the world, both in newly industrialized countries such as China, India, and Mexico and in developed countries such as the United States and various European nations. Though these therapies are often promoted as being established and effective, they generally have not received stringent regulatory oversight and have not been tested with rigorous trials designed to determine their safety and likely benefits. In the absence of substantiated claims, the potential for harm to patients - as well as to the field of stem cell research in general - may outweigh the potential benefits.

To explore these issues, the Institute of Medicine, the National Academy of Sciences, and the International Society for Stem Cell Research held a workshop in November 2013. Stem Cell Therapies summarizes the workshop. Researchers, clinicians, patients, policy makers, and others from North America, Europe, and Asia met to examine the global pattern of treatments and products being offered, the range of patient experiences, and options to maximize the well-being of patients, either by protecting them from treatments that are dangerous or ineffective or by steering them toward treatments that are effective. This report discusses the current environment in which patients are receiving unregulated stem cell offerings, focusing on the treatments being offered and their risks and benefits. The report considers the evidence base for clinical application of stem cell technologies and ways to assure the quality of stem cell offerings.

  1. ×

    Welcome to OpenBook!

    You're looking at OpenBook, NAP.edu's online reading room since 1999. Based on feedback from you, our users, we've made some improvements that make it easier than ever to read thousands of publications on our website.

    Do you want to take a quick tour of the OpenBook's features?

    No Thanks Take a Tour »
  2. ×

    Show this book's table of contents, where you can jump to any chapter by name.

    « Back Next »
  3. ×

    ...or use these buttons to go back to the previous chapter or skip to the next one.

    « Back Next »
  4. ×

    Jump up to the previous page or down to the next one. Also, you can type in a page number and press Enter to go directly to that page in the book.

    « Back Next »
  5. ×

    Switch between the Original Pages, where you can read the report as it appeared in print, and Text Pages for the web version, where you can highlight and search the text.

    « Back Next »
  6. ×

    To search the entire text of this book, type in your search term here and press Enter.

    « Back Next »
  7. ×

    Share a link to this book page on your preferred social network or via email.

    « Back Next »
  8. ×

    View our suggested citation for this chapter.

    « Back Next »
  9. ×

    Ready to take your reading offline? Click here to buy this book in print or download it as a free PDF, if available.

    « Back Next »
Stay Connected!